Novonesis slips after Q4 miss, 2026 uncertainty

Novozymes A/S

25/02/2026 08:25

** Shares in Novonesis NSISb.CO fall 3% after the Danish biosolutions group posted its Q4 results below estimates, and warned of a potentially lower consumer sentiment in 2026

** It posted its adjusted EBITDA for the quarter at 365 million euros ($430 million), against 375 million euros expected by consensus

** Q4 organic growth comes at 4%, while analysts expected 5.2% on average, and J.P. Morgan points to a "much weaker than expected" growth in the Agriculture, Energy & Tech businesses

** Novonesis expects its adjusted EBITDA margin in 2026 in the range of 37-38%, which Jefferies says implies an adjusted EBITDA of 1.64 billion euros at mid-point, below the consensus number of 1.67 billion euros

** "We expect slight share price pressure", the broker says

($1 = 0.8474 euros)

(Reporting by Boleslaw Lasocki)

((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))